Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-914832 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A (BMS-914832) | EXPERIMENTAL | - |
| Treatment B (BMS-914832 + diltiazem) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-914832 | DRUG | Tablets, Oral, 30 mg, once, 1 day |
| Diltiazem | DRUG | Tablets, Oral, 360 mg, once daily, 10 days |
Inclusion Criteria: * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations * Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avo...
BMS-914832 is an investigational small molecule being developed for the treatment of atrial fibrillation, a cardiovascular condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied to evaluate its safety and pharmacological properties in this patient population.
BMS-914832 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the drug's potential in treating atrial fibrillation.
BMS-914832 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied for its safety, tolerability, and pharmacokinetics in healthy volunteers and patients with atrial fibrillation.
BMS-914832 has one completed Phase 1 clinical trial registered under NCT01211808. This study, titled 'Effect of Diltiazem on Pharmacokinetics of BMS-914392,' enrolled 24 participants in the United States and evaluated the drug's interaction with diltiazem in healthy volunteers. The trial was controlled but not double-blinded.
The specific molecular target or mechanism of action for BMS-914832 has not been disclosed. As a small molecule being developed for atrial fibrillation, it is intended to address the cardiovascular condition, but its precise pharmacological action remains under investigation in clinical trials.